Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Barclays PLC

Barclays PLC grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 142,914 shares of the biopharmaceutical company's stock after acquiring an additional 12,533 shares during the quarter. Barclays PLC owned about 0.22% of Celldex Therapeutics worth $3,611,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CLDX. American Century Companies Inc. boosted its holdings in shares of Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after acquiring an additional 193,093 shares during the period. Renaissance Technologies LLC purchased a new position in Celldex Therapeutics during the 4th quarter worth $3,452,000. Sovran Advisors LLC purchased a new position in Celldex Therapeutics during the 4th quarter worth $2,867,000. Fisher Asset Management LLC lifted its stake in shares of Celldex Therapeutics by 20.9% in the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock worth $11,435,000 after acquiring an additional 78,145 shares during the period. Finally, Cinctive Capital Management LP boosted its holdings in shares of Celldex Therapeutics by 140.6% in the fourth quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company's stock valued at $2,055,000 after acquiring an additional 47,523 shares in the last quarter.

Celldex Therapeutics Stock Performance

CLDX stock traded down $0.12 during trading on Thursday, reaching $20.71. 621,747 shares of the company were exchanged, compared to its average volume of 883,780. The company has a market cap of $1.37 billion, a P/E ratio of -8.06 and a beta of 1.59. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The stock's 50 day moving average price is $19.11 and its 200 day moving average price is $23.34.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a report on Monday. They issued a "buy" rating and a $64.00 target price on the stock. The Goldman Sachs Group lowered their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, Morgan Stanley began coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $55.30.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.